口服Moxifloxacin後之休克

Moxifloxaci常用於呼吸道感染,是新的廣效fluroquinolone類抗生素,並有良好的組織穿透力。我們報告一位41歲紅斑性狼瘡(SLE)以及粟粒性肺結核(miliary tuberculosis)的亞洲女性病人,接受levofloxacin治療粟粒性肺結核,後改為每日口服400毫克moxifloxacin治療皮下結核性膿瘍。服藥後出現頭暈及休克症狀後住院治療。病情穩定後,在密切監測下口服200 ㎎ moxifloxacin,4小時後再度出現休克。排除其他可能的原因後,包括心因性休克(cardiogenic shock)、低血容性休克(hypovolemic shock)、敗血性休克...

Full description

Saved in:
Bibliographic Details
Published in台灣醫學 Vol. 16; no. 1; pp. 21 - 25
Main Authors 蘇富敏(Fu-Min Su), 張榮叁(Jung-San Chang), 林蔚如(Wei-Ru Lin)
Format Journal Article
LanguageChinese
Published 台灣 臺灣醫學會 01.01.2012
Subjects
Online AccessGet full text
ISSN1028-1916
DOI10.6320/FJM.2012.16(1).03

Cover

Abstract Moxifloxaci常用於呼吸道感染,是新的廣效fluroquinolone類抗生素,並有良好的組織穿透力。我們報告一位41歲紅斑性狼瘡(SLE)以及粟粒性肺結核(miliary tuberculosis)的亞洲女性病人,接受levofloxacin治療粟粒性肺結核,後改為每日口服400毫克moxifloxacin治療皮下結核性膿瘍。服藥後出現頭暈及休克症狀後住院治療。病情穩定後,在密切監測下口服200 ㎎ moxifloxacin,4小時後再度出現休克。排除其他可能的原因後,包括心因性休克(cardiogenic shock)、低血容性休克(hypovolemic shock)、敗血性休克(septic shock)、停止類固醇導致休克(steroid withdrawal-induced shock),以Naranjo probability scale評估認為是moxifloxacin導致休克,中止moxifloxacin並給予支持療法後,休克迅速獲得改善。moxifloxacin是一種fluoroquinolone類藥物,而fluoroquinolone類藥物可造成過敏性休克,大多數醫生認可moxifloxacin的安全性,但口服moxifloxacin造成這名病人的休克。如果患者服用門診醫囑開立的口服moxifloxacin後感到不適,醫生應警覺並仔細監測病人血壓,更應該事先告知患者,服藥後如果感到不適時,必須記錄血壓並尋求醫療協助。
AbstractList Moxifloxacin is a new fluoroquinolone antimicrobial agent with a broad spectrum of activity.Moxifloxacin attains good penetration into respiratory tissues and fluids. Therefore, moxifloxacin is commonly used in airway infection. We reported a patient developed unexpected shock after taking moxifloxacin orally. A 41-year-old Asian female patient with systemic lupus erythematosus (SLE) had received levofloxacin for miliary tuberculosis. Later, levofloxacin was replaced by oral moxifloxacin 400mg once daily for subcutaneous tuberculous abscess. Dizziness and hypotension developed later after oral intake of moxifloxacin and the patient was hospitalized. After the condition became stable, re-challenge of 200 mg moxifloxacin was done under close monitoring. Recurrent shock was noted 4 hours later. Possible causes of shock were excluded and moxifloxacin-induced shock was suggested by using the Naranjo Probability Scale. Moxifloxacin was discontinued and the shock was corrected rapidly. Anaphylactic shock has been as
Moxifloxaci常用於呼吸道感染,是新的廣效fluroquinolone類抗生素,並有良好的組織穿透力。我們報告一位41歲紅斑性狼瘡(SLE)以及粟粒性肺結核(miliary tuberculosis)的亞洲女性病人,接受levofloxacin治療粟粒性肺結核,後改為每日口服400毫克moxifloxacin治療皮下結核性膿瘍。服藥後出現頭暈及休克症狀後住院治療。病情穩定後,在密切監測下口服200 ㎎ moxifloxacin,4小時後再度出現休克。排除其他可能的原因後,包括心因性休克(cardiogenic shock)、低血容性休克(hypovolemic shock)、敗血性休克(septic shock)、停止類固醇導致休克(steroid withdrawal-induced shock),以Naranjo probability scale評估認為是moxifloxacin導致休克,中止moxifloxacin並給予支持療法後,休克迅速獲得改善。moxifloxacin是一種fluoroquinolone類藥物,而fluoroquinolone類藥物可造成過敏性休克,大多數醫生認可moxifloxacin的安全性,但口服moxifloxacin造成這名病人的休克。如果患者服用門診醫囑開立的口服moxifloxacin後感到不適,醫生應警覺並仔細監測病人血壓,更應該事先告知患者,服藥後如果感到不適時,必須記錄血壓並尋求醫療協助。
Author 蘇富敏(Fu-Min Su)
張榮叁(Jung-San Chang)
林蔚如(Wei-Ru Lin)
Author_xml – sequence: 1
  fullname: 蘇富敏(Fu-Min Su)
– sequence: 2
  fullname: 張榮叁(Jung-San Chang)
– sequence: 3
  fullname: 林蔚如(Wei-Ru Lin)
BookMark eNpdj81Kw0AUhWdRwVr7AIK41kXivTPJzGQpxfhDi5vuw0wyQ0dKAoli-wCuqhT37nwKQXyaxudwQlwJFw6Xc-7lfAdkUFalIeQIIeSMwnl6OwspIA2Rn-JZCGxAhghUBpgg3yfjpnEaUFCODOSQnLTbj5_311m1cnZZrVTuyvb7Zfe52X29tc-bQ7Jn1bIx4z8dkXl6OZ9cB9O7q5vJxTRQMooCG1vkCEoqATqRFIrCMqGjmFqWS2l8Rhq0FFHmsbIWhc2ViLXWlDKDnI3Icf92sX4yOlusa6OKDHxPoCLydtrbytXuwWX31WNd-jpZB9ZxZR0xYC8MEn_J_i1-BPsF9nJVIw
ContentType Journal Article
DBID 188
9RA
DOI 10.6320/FJM.2012.16(1).03
DatabaseName Chinese Electronic Periodical Services (CEPS)
HyRead台灣全文資料庫
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Shock after Oral Moxifloxacin Use
DocumentTitle_FL Shock after Oral Moxifloxacin Use
EndPage 25
ExternalDocumentID 00170274
10281916_201201_201203090013_201203090013_23_27
GroupedDBID 188
ALMA_UNASSIGNED_HOLDINGS
M~E
9RA
ID FETCH-LOGICAL-a844-f5f1610a8a70b9820ddf37b452f3c88e8448e1f2118c5aff17fca75bbb223e163
ISSN 1028-1916
IngestDate Thu Jul 31 11:53:00 EDT 2025
Tue Oct 01 22:51:49 EDT 2024
IsPeerReviewed false
IsScholarly false
Issue 1
Keywords Shock
不良反應
休克
adverse effect
fluoroquinolone
fluoroquinolones
moxifloxacin
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a844-f5f1610a8a70b9820ddf37b452f3c88e8448e1f2118c5aff17fca75bbb223e163
PageCount 5
ParticipantIDs hyweb_hyread_00170274
airiti_journals_10281916_201201_201203090013_201203090013_23_27
PublicationCentury 2000
PublicationDate 20120101
201201
PublicationDateYYYYMMDD 2012-01-01
PublicationDate_xml – month: 01
  year: 2012
  text: 20120101
  day: 01
PublicationDecade 2010
PublicationPlace 台灣
PublicationPlace_xml – name: 台灣
PublicationTitle 台灣醫學
PublicationTitle_FL Formosan Journal of Medicine
PublicationYear 2012
Publisher 臺灣醫學會
Publisher_xml – name: 臺灣醫學會
SSID ssib017261308
ssib002263207
ssib008679384
ssib004318135
ssib044762447
Score 1.5388489
Snippet Moxifloxaci常用於呼吸道感染,是新的廣效fluroquinolone類抗生素,並有良好的組織穿透力。我們報告一位41歲紅斑性狼瘡(SLE)以及粟粒性肺結核(miliary...
Moxifloxacin is a new fluoroquinolone antimicrobial agent with a broad spectrum of activity.Moxifloxacin attains good penetration into respiratory tissues and...
SourceID hyweb
airiti
SourceType Publisher
StartPage 21
SubjectTerms fluoroquinolone
moxifloxacin
TSCI
不良反應
休克
Title 口服Moxifloxacin後之休克
URI https://www.airitilibrary.com/Article/Detail/10281916-201201-201203090013-201203090013-23-27
http://www.hyread.com.tw/hypage.cgi?HYPAGE=search/search_detail_new.hpg&dtd_id=3&sysid=00170274
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LjtMw0CoLBy4IxCKWx2oPjASHlMRxYvuEkmyqVaVygCL2VuWpVkJbCVppdw_cOC0IcefGVyAhvoXDlu9gxklbsyDEgmSlaeyZsT3OeGYythm7pwOcVDPuO6grlI5Qbu6g1uo60s3ynPZXr81hE4PH4d4z0d8P9judb1bU0nyWd4vj364r-Reu4jPkK62SPQdnV0jxAd4jf_GKHMbrX_EY0gBUDyIf0hB0Amp3MD2c1C-mh1mBBj_mximoBFIBsQYVm5sEtGcAMcW2btpii11IJSqYBi1ChRDFlBXtQryKe4VUgVagpMnpGSJYBYOAq97cGUxQbswtP4OpTQJxQAUjTGlLDylx1UeZ4zxFWZM0DmwLDNGmoKWhKEBHhmIIiiPY82riPJmTY2EJ0jowTCSI7cAgcKxtHP2hccte9C1JTW5BNDbDn0R5-MuQXcpla4ZvVlqfnTtCn1OwZa8_oIA_3iWnBvUAbYK7nixXIYxEn8iPqLDrNT--q0mnPvMHk7zALnIpTSDB4HVqKVBE1vrujCLWsxRY2g7RX68kRm2T7L2VxBQC5zJhTtFb9Ufz6Z7QPrTact970KWD4S5lE9osC02x8VET9LvUpYZX2ZXWCNqJmhF9jXWOx9fZ9uL9p-8f39kjePH17ennk9MvHxZvTjbZsJcOkz2nPb3DyZQQTh3UaEy4mcqkm2vUM8uy9mUuAl77hVIVllGVV3M0cIsgq2tP1kUmgxwlBPcrtBJusI2D6UF1k-3osgqUFqoUMhAeAheZjxhDXnl5WFZyiz1qWjVq381Xo3NyZ4ttmu4YjY_QVCtHZlcpLsWt_8Z8m11ej_k7bGP2cl7dRTV2lm-bkfADKz1pRg
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%8F%A3%E6%9C%8DMoxifloxacin%E5%BE%8C%E4%B9%8B%E4%BC%91%E5%85%8B&rft.jtitle=%E5%8F%B0%E7%81%A3%E9%86%AB%E5%AD%B8&rft.au=%E8%98%87%E5%AF%8C%E6%95%8F%28Fu-Min+Su%29&rft.au=%E5%BC%B5%E6%A6%AE%E5%8F%81%28Jung-San+Chang%29&rft.au=%E6%9E%97%E8%94%9A%E5%A6%82%28Wei-Ru+Lin%29&rft.date=2012-01-01&rft.pub=%E8%87%BA%E7%81%A3%E9%86%AB%E5%AD%B8%E6%9C%83&rft.issn=1028-1916&rft.volume=16&rft.issue=1&rft.spage=21&rft.epage=25&rft_id=info:doi/10.6320%2FFJM.2012.16%281%29.03&rft.externalDocID=10281916_201201_201203090013_201203090013_23_27
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fwww.airitilibrary.com%2Fjnltitledo%2F10281916-c.jpg